Drug intelligence / Profile preview

RO5036505

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous

Overview

RO5036505 is a synthetic small molecule drug that was developed by Hoffmann-La Roche for the treatment of moderate to severe asthma. It was investigated as an intravenous agent in clinical trials targeting patients with inadequately controlled asthma despite standard therapy. The precise mechanism of action and molecular target of RO5036505 have not been publicly disclosed, and it does not represent a novel mechanism or modality based on available data. Development reached Phase 2 clinical trials but was ultimately discontinued before approval[2][3][4][5].

Beyond the preview

Go deeper on RO5036505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5036505.

Explore the full profile